Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this observational study is to learn about the HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer. The main question it aims to answer is: \- Does the heterogeneity of HER2 expression level and spatial distribution in different tissues affect the efficacy of trastuzumab deruxtecan in metastatic breast cancer?
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z zaawansowanym rakiem piersi, który nie może być operacyjnie usunięty
- •Leczeni lekiem T-DXd (trastuzumab deruxtecan), niezależnie od linii leczenia i poziomu receptorów HER2
- •Dostępne informacje o badaniu immunohistochemicznym HER2 z pierwotnego guza lub przerzutów
- •Widoczne zmiany chorobowe, których odpowiedź na leczenie można ocenić za pomocą badań obrazowych
- •Możliwość regularnego monitorowania przebiegu choroby i przeżycia
✗ Disqualifies
- •Brakujące podstawowe informacje kliniczne lub wyniki badania HER2
- •Brakujące wyniki badania patologicznego pierwotnego guza lub przerzutów
- •Brak zmian vidocznych do oceny odpowiedzi na leczenie T-DXd
- •Przerwanie leczenia T-DXd z powodu poważnych działań niepożądanych
- •Brak możliwości regularnego śledzenia przebiegu choroby pacjenta
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- May 22, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (26)
Yale Cancer Center
New Haven, United States
Dana-Farber Cancer Institute, Harvard Medical School
Boston, United States
Fujian Cancer Hospital, Fujian Medical University
Fuzhou, China
The 10th Affiliated Hospital of Southern Medical University
Dongguan, China
The First People's Hospital of Foshan
Foshan, China
The Sixth Affiliated Hospital, School of Medicine, South China University of Technology.
Foshan, China
Sun Yat-sen University Cancer Center
Guangzhou, China
The Affiliated Panyu Central Hospital, Guangzhou Medical University
Guangzhou, China
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, China
The Affiliated Cancer Hospital, Guangzhou Medical University
Guangzhou, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, China
Cancer Hospital of Shantou University Medical College
Shantou, China
Yuebei People's Hospital of Shantou University
Shaoguan, China
National Cancer Center Shenzhen Hospital
Shenzhen, China
Shenzhen People's Hospital
Shenzhen, China
Zhongshan City People's Hospital
Zhongshan, China
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, China
Changde Hospital, Xiangya School of Medicine, Central South University
Changde, China
Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, China
The Second Xiangya Hospital of Central South University
Changsha, China
The First Affiliated Hospital, Hengyang Medical School, University of South China
Hengyang, China
Affiliated Cancer Hospital of Inner Mongolia Medical University
Hohhot, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Xinhua Hospital Afliated to Shanghai Jiaotong University
Shanghai, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Trial contact
Xiaoming Xie, MD, PhD
Yutian Zou, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.